Share ownership Iqvia Holdings Inc.

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-12-05 pm EST			5-day change	1st Jan Change
225.85 ^USD	+0.41%		-1.81%	+14.93%

Dec. 02	Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Albuterol Sulfate Inhalation Aerosol	CI
Dec. 02	Iqvia announces strategic collaboration with AWS, naming AWS as preferred agentic cloud provider to power next-generation AI platform	RE

Share class: Iqvia Holdings Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	258,200,000	174,409,440 ( 67.55 %)	82,100,000 ( 31.8 %)	67.55 %

Major shareholders: Iqvia Holdings Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 11.44 %	19,490,633	11.44 %	4 219 M $
Harris Associates LP 6.687 %	11,387,265	6.687 %	2 465 M $
BlackRock Advisors LLC 6.425 %	10,942,508	6.425 %	2 369 M $
STATE STREET CORPORATION 4.433 %	7,548,921	4.433 %	1 634 M $
GIC Pte Ltd. (Investment Management) 3.841 %	6,541,387	3.841 %	1 416 M $
Geode Capital Management LLC 2.555 %	4,350,518	2.555 %	942 M $
Canada Pension Plan Investment Board 2.417 %	4,115,564	2.417 %	891 M $
Fidelity Management & Research Co. LLC 2.152 %	3,665,476	2.152 %	793 M $
AllianceBernstein LP 2.112 %	3,597,572	2.112 %	779 M $
Boston Partners Global Investors, Inc. 2.088 %	3,556,708	2.088 %	770 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	82.01%
Other	11.27%
State Street Corp.	4.43%
Individuals	0.89%
Sumitomo Mitsui Trust Group, Inc.	0.47%
Manulife Financial Corp.	0.3%
Schweizerische Nationalbank	0.29%
Governments	0.15%
Skandinaviska Enskilda Banken AB	0.12%
Associated Banc-Corp	0.1%
SEI Investments Co.	0.08%
Swedbank AB	0.05%
Danske Bank A/S	0.05%
Polar Capital Holdings Plc	0.04%
Markel Group, Inc.	0.03%
The Bank of Nova Scotia	0.02%
Fifth Third Bancorp	0.01%
Regions Financial Corp.	0.01%
Banque Cantonale Vaudoise	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	71.72%
United Kingdom	8.75%
Canada	4.63%
Singapore	3.97%
Denmark	1.52%
France	1.2%
Australia	1.14%
Norway	1.11%
Japan	0.98%
Individuals	0.89%
Switzerland	0.62%
Sweden	0.6%
Bermuda	0.57%
Luxembourg	0.46%
Netherlands	0.45%
Belgium	0.27%
Germany	0.25%
South Korea	0.25%
Ireland	0.22%
Spain	0.21%
Finland	0.15%
Austria	0.06%
South Africa	0.06%
Italy	0.05%
New Zealand	0.05%
Hong Kong	0.04%
Mexico	0.03%
Czech Republic	0.03%
Slovenia	0.02%
India	0.01%
China	0.01%
Taiwan	0.01%

Based on 1000 largest holdings

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (55.4%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (4.7%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (47.8%), Europe and Africa (31.9%) and Asia/Pacific (20.3%).

Employees

91,000

Sector

Biotechnology & Medical Research

Calendar

Feb. 17 - Q4 2025 Earnings Release (Projected)

More about the company